Float Short %

25.04

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

-2.9

EPS Last/This Y

11.41

EPS This/Next Y

16.11

Price

8.31

Target Price

23.98

Analyst Recom

3.2

Performance Q

-13.35

Relative Volume

0.27

Beta

0.7

Ticker: BLUE

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	BLUE	9.18	0.08	2.05	126481
2024-12-20	BLUE	8.49	0.08	0.02	127099
2024-12-23	BLUE	7.61	0.08	0.02	120083
2024-12-24	BLUE	7.96	0.08	0.23	120820
2024-12-26	BLUE	8.62	0.08	0.19	120785
2024-12-27	BLUE	8.75	0.08	0.34	120707
2024-12-30	BLUE	7.86	0.08	0.17	120643
2024-12-31	BLUE	8.34	0.08	0.33	120694
2025-01-02	BLUE	8.71	0.08	0.26	120741
2025-01-03	BLUE	9.18	0.08	0.13	120782
2025-01-06	BLUE	9.94	0.08	0.07	121055
2025-01-07	BLUE	9.06	0.08	0.29	121000
2025-01-08	BLUE	8.46	0.08	0.00	121059
2025-01-09	BLUE	8.46	0.08	0.00	121059
2025-01-10	BLUE	8.49	0.08	0.44	121064
2025-01-13	BLUE	8.5	0.08	0.03	121238
2025-01-14	BLUE	8.03	0.08	0.00	121276
2025-01-15	BLUE	8.29	0.08	0.21	121314
2025-01-16	BLUE	8.3	0.08	13.13	121177
2025-01-17	BLUE	8.35	0.08	0.21	121082
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	BLUE	9.20	60.7	-	-1.40
2024-12-20	BLUE	8.49	60.7	-	-27.19
2024-12-23	BLUE	7.66	63.2	-	-27.19
2024-12-24	BLUE	7.79	63.2	-	-27.19
2024-12-26	BLUE	8.78	63.2	-	-27.19
2024-12-27	BLUE	8.77	63.2	-	-27.19
2024-12-30	BLUE	7.81	63.2	-	-27.19
2024-12-31	BLUE	8.31	63.2	-	-27.19
2025-01-02	BLUE	8.71	63.2	-	-27.19
2025-01-03	BLUE	9.22	63.2	-	-27.19
2025-01-06	BLUE	9.91	63.2	-	-27.19
2025-01-07	BLUE	9.03	63.2	-	-27.19
2025-01-08	BLUE	8.46	63.2	-	-27.19
2025-01-09	BLUE	8.46	63.2	-	-27.19
2025-01-10	BLUE	8.48	63.2	-	-27.19
2025-01-13	BLUE	8.49	63.2	-	-27.19
2025-01-14	BLUE	8.03	63.2	-	-27.19
2025-01-15	BLUE	8.30	63.2	-	-27.19
2025-01-16	BLUE	8.28	63.2	-	-27.19
2025-01-17	BLUE	8.31	63.2	-	-27.19
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	BLUE	-31.63	0	1.29
2024-12-20	BLUE	-31.63	0	1.29
2024-12-23	BLUE	-33.44	0	25.71
2024-12-24	BLUE	-33.44	0	25.71
2024-12-26	BLUE	-31.27	0	25.71
2024-12-27	BLUE	-31.63	0	25.71
2024-12-30	BLUE	-31.63	0	25.71
2024-12-31	BLUE	-31.63	0	25.71
2025-01-02	BLUE	-30.36	0	25.71
2025-01-03	BLUE	-31.63	0	25.71
2025-01-06	BLUE	-30.46	0	25.71
2025-01-07	BLUE	-30.46	0	25.71
2025-01-08	BLUE	-31.72	0	25.71
2025-01-09	BLUE	-31.72	0	25.71
2025-01-10	BLUE	-31.72	0	25.71
2025-01-13	BLUE	-31.72	0	25.04
2025-01-14	BLUE	-31.72	0	25.04
2025-01-15	BLUE	-31.72	0	25.04
2025-01-16	BLUE	-31.72	0	25.04
2025-01-17	BLUE	-31.72	0	25.04
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.31

Avg. EPS Est. Current Quarter

-5.75

Avg. EPS Est. Next Quarter

-3.21

Insider Transactions

-31.72

Institutional Transactions

Beta

0.7

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.4

Max Drawdown 5-Year %

-99.5

Target Price

23.98

P/E

Forward P/E

PEG

P/S

1.53

P/B

P/Free Cash Flow

EPS

-35.97

Average EPS Est. Cur. Y

-27.19

EPS Next Y. (Est.)

-11.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-551.26

Relative Volume

0.27

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

0.9

EPS 1 30Days Diff

-0.19

EBIT Estimation

bluebird bio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 375

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

stock quote shares BLUE – bluebird bio, Inc. Stock Price stock today

news today BLUE – bluebird bio, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BLUE – bluebird bio, Inc. yahoo finance google finance

stock history BLUE – bluebird bio, Inc. invest stock market

stock prices BLUE premarket after hours

ticker BLUE fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: BLUE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y